Drug Discovery World

JANUARY 15, 2024

The announcement follows the news that Merck agreed a deal with Inspirna for colorectal cancer drug ompenaclid (RGX-202). “At This agreement reflects the creativity and commitment of scientists and clinical development teams at Harpoon. The study is also evaluating HPN328 in combination with atezolizumab in patients with SCLC.

Clinical Development 105

Clinical Development Clinical Trials Clinical Trials Development 105

Drug Discovery World

SEPTEMBER 22, 2023

News round-up for 18-22 September by DDW Digital Content Editor Diana Spencer. UK scientists prepare for Nipah virus clinical trial The University of Oxford has revealed that researchers are currently in the advanced stages of preparing for a clinical trial of a Nipah vaccine using the ChAdOx1 vector.

Drugs 52

Drugs Vaccination Vaccine Clinical Trials 52

Drug Discovery World

AUGUST 25, 2023

News round-up for 21-25 August by DDW Digital Content Editor Diana Spencer. NLRP3 inhibitor for neuroinflammation enters trials The Phase I clinical trial of VENT-02, an oral, brain-penetrant NLRP3 inhibitor from Ventus Therapeutics, has launched with the dosing of the first patient.

Drugs 52

Drugs Clinical Trials Clinical Trials Trials 52

Drug Discovery World

MARCH 10, 2023

News round-up for 6-10 March by DDW Digital Content Editor Diana Spencer. Perhaps most interestingly this week, after previous caution over in vivo gene therapy trials, the FDA has given the go ahead to Intellia Therapeutics to study NTLA-2002 in hereditary angioedema (HAE).

In-Vivo 52

In-Vivo Clinical Trials Clinical Trials Drugs 52

Drug Discovery World

AUGUST 11, 2023

News round-up for by DDW Digital Content Editor Diana Spencer. The news headlines this week reflect the level of interest in cell & gene therapies (CGT) in the sector, particularly CAR-T, but also the importance of research collaborations to bring these therapies to patients.

Gene Therapy 52

Gene Therapy Drugs Clinical Trials Clinical Trials 52

Drug Discovery World

JANUARY 26, 2024

News round-up for 22-26 January by DDW Digital Content Editor Diana Spencer. Phase IIa trial launches in advanced pancreatic cancer The Phase IIa ACCENT trial has launched to explore the activity of focal adhesion kinase (FAK) inhibitor narmafotinib in combination with standard-of-care chemotherapy in advanced pancreatic cancer patients.

Drugs 52

Drugs Trials Research Development 52

Drug Discovery World

JUNE 16, 2023

News round-up for 5-9 June by DDW Multimedia Editor Megan Thomas. Patient dies in cell therapy clinical trial A Phase I clinical trial testing a CAR-T cell therapy treatment in children with acute myeloid leukaemia (AML) has been paused due to a patient’s death.

FDA Approval 52

FDA Approval Drugs Clinical Trials Clinical Trials 52

Drug Discovery World

JUNE 2, 2023

News round-up for 29 May – 2 June by DDW Digital Content Editor Diana Spencer. With National Cancer Research Month coming to an end and the American Society of Clinical Oncology Annual Meeting currently taking place in Chicago (2-6 June), it’s been another busy week for cancer drug development news.

Drugs 52

Drugs HR Antibody Clinical Trials 52

World of DTC Marketing

JUNE 28, 2021

The clinical evidence supporting the approval of the drug is at best “weak.” ” How could the FDA approve a drug with such poor clinical data? A couple of years ago, I was working with a client who was in the process of developing an anti-depressant that could be taken once a week. ” It was dropped.

Drugs 194

Drugs FDA Approval Clinical Trials Clinical Trials 194

Drug Discovery World

JANUARY 18, 2023

The first patient has been treated in everImmune’s Phase I clinical trial evaluating its oncobiotic drug candidate Oncobax AK in lung and kidney cancer patients. . The aim of the trial is to assess the toxicity and efficacy of Oncobax AK when administered alongside an immunotherapy treatment. .

Drugs 52

Drugs Clinical Trials Clinical Trials Bacteria 52

Drug Discovery World

MARCH 29, 2024

News round-up for 25-29 March by DDW Digital Content Editor Diana Spencer. Potential first-in-class therapeutic for urea cycle disorders enters trial CAMP4 Therapeutics has dosed the first participant in its Phase I clinical study of CMP-CPS-001, a potential first-in-class therapeutic for the treatment of urea cycle disorders (UCDs).

Drugs 52

Drugs FDA Approval Antibody Trials 52

Drug Discovery World

DECEMBER 8, 2023

News round-up for 4-8 December by DDW Digital Content Editor Diana Spencer. Potentially game-changing schizophrenia drug enters trials A potential schizophrenia treatment, discovered at Vanderbilt University in Tennessee in the US, has been cleared by the US Food and Drug Administration for use in Phase I clinical trials.

Drugs 52

Drugs DNA Clinical Trials Clinical Trials 52

Velocity Clinical Research

JUNE 12, 2023

If you snore loudly and feel tired, even after a full night's sleep, you might have sleep apnea, according to The Mayo Clinic and other healthcare experts. I treat a lot of people for sleep apnea, and I can see the ir difficulties in using continuous positive airway pressure (CPAP) therapy as a permanent solution ,” he explains. “As

Clinical Trials 98

Clinical Trials Clinical Trials Clinical Research Trials 98

Drug Discovery World

JANUARY 23, 2023

Clinical trials have led our news section this week, with positive results announced from several Phase I and II studies. There was good news from Alto Neuroscience, everImmune, Avacta and Abionyx, though unfortunately things are not looking so rosy for Janssen’s HIV vaccine candidate.

Clinical Trials 52

Clinical Trials Clinical Trials Vaccination Vaccine 52

Pharmaceutical Technology

DECEMBER 28, 2022

Gilead Oncology Therapeutic Area head senior vice president Bill Grossman said: “Today’s news about GS-1811 further demonstrates our commitment to our rapidly evolving oncology franchise and mission of pioneering next-generation medicines for people with cancer. “GS-1811,

Licensing 130

Licensing Licensing Clinical Trials Clinical Trials 130

Pharmaceutical Technology

SEPTEMBER 23, 2022

More than double the volume of Fennec’s shares were traded on the day of the approval news in comparison to 19 September. Pedmark clinical trials. Fennec Pharmaceuticals assessed Pedmark in the two multicentre clinical trials SIOPEL 6 (NCT00652132) and COG ACCL0431 (NCT00716976).

Drugs 130

Drugs FDA Approval Clinical Trials Clinical Trials 130

Drug Discovery World

FEBRUARY 2, 2024

News round-up for 29 January – 2 February by DDW Digital Content Editor Diana Spencer. Phase I trial for first-in-class bispecific antibody for cancer Onward Therapeutics has announced the Phase I clinical trial of OT-A201, a first-in-class bispecific antibody targeting two immune checkpoints is in progress.

Drugs 52

Drugs Antibody Clinical Trials Clinical Trials 52

Drug Discovery World

MARCH 24, 2023

News round-up for 20-24 March by DDW Digital Content Editor Diana Spencer. There have also been positive trial results announced in prostate cancer, pancreatic cancer and breast cancer. This week we have seen a number of developments in the treatment of solid tumours hitting the headlines.

Drugs 52

Drugs Hormones Trials Research 52

XTalks

FEBRUARY 20, 2024

Safety assessments of sibeprenlimab have revealed no evidence of adverse toxic effects or clinically significant immunosuppression. At month 12, the percentage of patients achieving clinical remission was 7.9 How Does Sibeprenlimab Work? percent (three of 38 patients), 12.2 percent (five of 41 patients), 26.3

Clinical Trials 59

Clinical Trials Clinical Trials FDA Approval Trials 59

Drug Discovery World

OCTOBER 27, 2023

News round-up for 23-27 October by DDW Digital Content Editor Diana Spencer. My news highlights this week feature a variety of treatment approaches, from cell therapy and antibody-drug conjugate to autotaxin inhibitor and arenaviral vaccine, all entering early in-human clinical trials to treat a range of diseases.

Drugs 52

Drugs Antibody Vaccination Vaccine 52

World of DTC Marketing

NOVEMBER 27, 2020

Pfizer and Moderna have provided data from their large-scale Phase 3 trials only via news releases , which contained the highly promising news that both vaccines were 90 percent effective or more and have not presented any serious safety concerns. Science by press release.

Vaccination 208

Vaccination Vaccine Pharma Companies Trials 208

Drug Discovery World

AUGUST 19, 2022

News round-up by DDW Editor Reece Armstrong for 15-19 August. Covid booster approvals, positive results for Malaria vaccines and new CEOs are some of the stories in this week’s news round-up. . Positive results for US Malaria vaccine, trial shows . Respira appoints new CEO to drive inhalable therapeutics.

Drugs 52

Drugs Vaccination Vaccine Medicine 52

Drug Discovery World

JUNE 29, 2023

To mark the occasion, this article summarises the most recent news about the ways drug discovery is improving wellbeing and mental health through innovative new treatments and therapies. Another Phase IIa trial will evaluate LYT-300 in patients with moderate to severe PPD.

Drugs 52

Drugs Trials Clinical Trials Clinical Trials 52

BioTech 365

SEPTEMBER 6, 2021

DGAP-News: Heidelberg Pharma AG / Key word(s): Miscellaneous 07.09.2021 / 07:21 The issuer is solely responsible for the content of this announcement. PRESS RELEASE Heidelberg Pharma provides update on Phase I/IIa clinical trial with ATAC candidate HDP-101 in the … Continue reading →

Clinical Trials 40

Clinical Trials Clinical Trials Trials 40

XTalks

MAY 24, 2022

It is predicted that there are 5000 new cases of HIV infection every day, and 500 of these happen in children. There has been a lengthy search to find an HIV cure and there have been a few promising trials, including the stem cell transplantation reported at the 2022 Conference on Retroviruses and Opportunistic Infections (CROI-2022).

Drugs 98

Drugs Clinical Trials Clinical Trials Trials 98

BioTech 365

JULY 19, 2021

DGAP-News: Heidelberg Pharma AG / Key word(s): Miscellaneous 19.07.2021 / 16:15 The issuer is solely responsible for the content of this announcement. PRESS RELEASE Paul Ehrlich Institute Allows Heidelberg Pharma to Start a Phase I/IIa Clinical Trial with ATAC Candidate … Continue reading →

Clinical Trials 40

Clinical Trials Clinical Trials Trials 40

XTalks

FEBRUARY 22, 2024

“We are encouraged by the FDA’s acceptance of the BLA as we endeavor to make datopotamab deruxtecan the first TROP2-directed ADC approved to treat patients with nonsquamous NSCLC after disease progression on prior systemic therapy,” said Susan Galbraith, executive VP of Oncology R&D at AstraZeneca, in the company’s news release.

Antibody 59

Antibody Clinical Trials Clinical Trials Trials 59

Drug Discovery World

SEPTEMBER 29, 2023

News round-up for 25-29 September by DDW Digital Content Editor Diana Spencer. The top stories: €27.3M to advance monoclonal antibody for autoimmune diseases AbolerIS Pharma has raised €27.3 million in a Series A financing led by Caixa Capital Risc and co-led by Sound Bioventures and Newton Biocapital.

In-Vivo 52

In-Vivo Drugs Antibody Clinical Trials 52

pharmaphorum

JANUARY 13, 2023

And as I look out the window at that snow, my travel-addled brain can’t help but see it as a metaphor for pharma in 2023: a crisp white, wide canvas laden with possibilities, but also one that’s going to require a lot of immediate, hard work from me if I want to be a responsible homeowner. I deserve it. But enough vagaries.

Clinical Trials 96

Clinical Trials Clinical Trials Gene Therapy Trials 96

Drug Discovery World

DECEMBER 15, 2023

News round-up for 11-15 December by DDW Digital Content Editor Diana Spencer. New data for relapsed/refractory follicular lymphoma treatment Genmab and AbbVie have announced updated data presented at ASH from the companies’ ongoing Phase I/II EPCORE NHL-1 clinical trial investigating epcoritamab (DuoBody CD3xCD20).

Drugs 52

Drugs Clinical Trials Clinical Trials Manufacturing 52

XTalks

MAY 31, 2023

Headquartered in California, Acelyrin is a late-stage clinical biopharmaceutical company dedicated to expediting the development and delivery of groundbreaking medicines in the field of immunology. The success of Acelyrin can be attributed to its industry-leading immunology portfolio and a robust pipeline of clinical and preclinical programs.

Clinical Trials 97

Clinical Trials Clinical Trials Trials Production 97

Drug Discovery World

APRIL 21, 2023

News round-up for 16-21 April by DDW Digital Content Editor Diana Spencer. The news stories dominating the headlines this week have been the breaking developments in cancer drug discovery announced at the American Association of Cancer Research (AACR) Annual Meeting, which was held in Florida, US from 14-19 April.

Drugs 52

Drugs Antibody Clinical Trials Clinical Trials 52

Drug Discovery World

AUGUST 26, 2022

News round-up for 21-25 August by DDW Editor Reece Armstrong. A treatment for Monkeypox, spider venom for drug discovery and funding for international start-ups are some of the stories in this week’s news round-up. Bayer to advance Huntington’s Disease gene therapy trial . Covid researchers launch Monkeypox study .

Gene Therapy 52

Gene Therapy Drugs Life Science Gene 52

WCG Clinical

SEPTEMBER 11, 2023

Listen and Subscribe: Apple PodCASTs Spotify Google PoDCASTS About this episode: In episode three of WCG Talks Trials , two WCG experts discuss key findings from the 2023 Avoca State of the Industry Report , which provides a 360-degree view on motivators and deterrents to clinical trial participation. Gina DiCindio: Sure.

Clinical Trials 59

Clinical Trials Clinical Trials Trials Clinical Research 59

ACRP blog

AUGUST 30, 2023

Food and Drug Administration (FDA) seems to be approving drugs after fewer trials (accelerated approval) and releasing less data from those trials, one experienced principal investigator (PI) cautions that public perceptions of clinical research may take a hit.

Clinical Trials 69

Clinical Trials Clinical Trials Trials Drugs 69

Drug Discovery World

DECEMBER 16, 2022

News round-up for 12-16 December by DDW Digital Content Editor Diana Spencer. An immunotherapy that uses a new targeted approach to kill bone marrow cancer cells was successful in as many as 73% of patients in two clinical trials. . New dermatitis treatment shows promising long-term results . The top stories: .

Drugs 52

Drugs Vaccination Vaccine Genetics 52

Pharmaceutical Technology

APRIL 4, 2023

Next generation EGFR inhibitors in development News of this agreement followed Scorpion’s announcement of its development plans for STX-241. Another biotech, Black Diamond Therapeutics is on track to give a clinical update on its inhibitor BDTX-1535, which is in a Phase I trial, in H2 2023.

Cosmetics 130

Cosmetics Development Licensing Licensing 130